Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has r
The individuals noted below were elected as Directors of the Company. The Company would like to welcome Peter Edwards to the Board of Directors. The Company would also like to extend its sincere tha
Shareholders will not be able to attend the AGM in-person at a physical location. To be admitted to the virtual AGM, shareholders need to visit www.virtualshareholdermeeting.com/AEZS2020 and enter th
The Company also provided an update on its clinical program to develop macimorelin for the diagnosis of child-onset growth hormone deficiency (“CGHD”), an area of significant unmet need, and its p

One Biotech Stock For 2020

11:30pm, Sunday, 03'rd May 2020
FDA has just fast-tracked research on an exciting new mental health treatment, and one small company is making moves to secure its place as an early mover in this revolution
Gilead Sciences’ antiviral drug remdesivir showed “quite good news”, according to White House health advisor Dr. Anthony Fauci. Assistant Professor in Department of Health Policy and Management
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 15.) * Bio-Rad Laboratories, Inc. Class B Common Stock
CHARLESTON, S.C., April 15, 2020 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company.
A live audio webcast of the presentation will be available on the Events and Presentations page of the Investors section of the Company’s website (www.zentaris.com). The Company’s lead product, M
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE